Samsung Bioepis — Deal History & Benchmarks
Market Analysis
Samsung Bioepis has been involved in 2 transactions totaling $1.0B across Women's Health, Ophthalmology. As a licensee (in-licensor/acquirer), they have demonstrated a preference for licensing partnerships.
Key transactions include Organon ($800M, 2024), Tarsus Pharmaceuticals ($210M, 2022).
Their deal activity is concentrated in Women's Health (50%) with Monoclonal Antibody and Small Molecule assets representing their most common deal types.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How many deals has Samsung Bioepis done?
What is Samsung Bioepis's typical deal structure?
What therapeutic areas does Samsung Bioepis focus on?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.